Drug Trial Radar · NCT06211634
A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
57
Planned (sponsor's estimate)
Start
Dec 13, 2022
Primary completion
Aug 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Hemab ApSIndustry
- Sponsor type
- Industry
- First posted
- Jan 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 67 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia. The main questions it aims to answer are: * Parts A, B, and C: To determine the safety and tolerability of HMB-001 * Part A: To establish the dose level(s) and dosing interval(s) of HMB-001 to be investigated in Parts B and C * Parts B and C: To estimate the ability of HMB-001 to prevent the number and severity of bleeds Part A will assess differing singular doses of HMB-001 in small groups of participants. The dose administered to a newly enrolled participant (or groups of participants) may only increase if analysis of data from previous dosing shows it is safe to do so. The planned duration of participation in Part A is approximately 6 months, which consists of a Screening Period, an optional Run-in Observation Period, and a follow-up period of 8 weeks. Part B is similar to Part A as it involves testing different dose levels of HMB-001 in small groups of participants. However, in Part B, HMB-001 is given multiple times over a 3-month period, either weekly, every 2 weeks, or every 4 weeks. Part B consists of a Screening Period, a Run-in Observation Period, a 3-month Treatment Period, and a Safety Follow-up following the last dose of HMB-001. Part C is open to participants from Part B and consists of approximately a 18-month Treatment Period and a Safety Follow-up following the last dose of HMB-001.
Conditions
- Glanzmann Thrombasthenia
Interventions
HMB-001Drug
HMB-001 is a bispecific antibody being developed as a prophylactic treatment option to prevent and reduce bleeding events in patients with Glanzmann thrombasthenia.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Safety as assessed by the incidence of treatment-emergent adverse events (TEAEs)Time frame: From baseline to Day 57
- Part A: Safety as assessed by the changes in physical examinations, vital signs, clinical laboratory assessments, and ECG parametersTime frame: From baseline to Day 57
- Part B: Safety as assessed by the incidence of treatment-emergent AEsTime frame: From baseline to Day 106/Early Termination (ET)/End of Study (EOS)
- Part B: Safety as assessed by the changes in physical examinations, vital signs, clinical laboratory assessments, and ECG parametersTime frame: From baseline to Day 106/ET/EOS
- Part B: Preliminary prophylactic effect of HMB-001 as assessed via Bleed frequency: annualized bleed rate (ABR)Time frame: From baseline to Day 106/ET/EOS
- Part B: Preliminary prophylactic effect of HMB-001 as assessed via Bleed frequency: annualized treated bleed rate (ATBR)Time frame: From baseline to Day 106/ET/EOS
- Part C: Safety as assessed by the incidence of treatment-emergent AEsTime frame: Day 99 to Day 687/Early Termination (ET)/ENdo of Study (EOS)
- Part C: Safety as assessed by the changes in physical examinations, vital signs, clinical laboratory assessments, and ECG parametersTime frame: Day 99 to Day 687/Early Termination (ET)/ENdo of Study (EOS)
- Part C: Preliminary prophylactic effect of HMB-001 as assessed via Bleed frequency: annual treated bleed rate (ATBR) and annualized bleed rate (ABR)Time frame: Day 99 to Day 687/Early Termination (ET)/ENdo of Study (EOS)
Locations
17 sites in 6 countries. Site status is shown where the registry gives one.
University of California, San Diego (UCSD) (Part B/C)
La Jolla, California
Tulane University Medical Center (Part B/C)
New Orleans, Louisiana
Mayo Clinic - Rochester (Part B/C)
Rochester, Minnesota
Hemophilia Center of Western Pennsylvania (HCWP) (Part B/C)
Pittsburgh, Pennsylvania
Washington Institute for Coagulation (Part B/C)
Seattle, Washington
University Hospital Leuven - Campus Gasthuisberg (Part B/C)
Leuven, Belgium
AP-HP Hopital Bicetre (Part B/C)
Le Kremlin-Bicêtre, France
AP-HM - Hopital de la Timone
Marseille, France
AP-HP Hopital Necker-Enfants Malades (Part B/C)
Paris, France
Azienda Ospedaliero-Universitaria Careggi (Part B/C)
Florence, Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano (Part B/C)
Milan, Italy
Universitair Medisch Centrum Utrecht (Part B/C)
Utrecht, Netherlands
Queen Elizabeth Hospital Birmingham (Part B/C)
Birmingham, United Kingdom
Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom
Richmond Pharmacology Ltd (Part A/B/C)
London, United Kingdom
Royal Free London NHS Foundation Trust (Part B/C)
London, United Kingdom
The Royal London Hospital (Part B/C)
Whitechapel, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.